Last updated: April 25, 2026
Who Supplies Pyrazinamide for Pharmaceutical and API Use?
Pyrazinamide is a commodity-style active pharmaceutical ingredient (API) used primarily in tuberculosis (TB) therapy. Supply tends to be handled by large Asian API manufacturers plus specialty chemical producers and toll manufacturers that can deliver technical-grade material, USP/BP/EP-grade API, or dossier-supported API batches. Below is a procurement-focused map of supplier types and typical sourcing channels used for pyrazinamide.
What supplier categories cover pyrazinamide procurement?
| Supplier type |
What they sell |
Typical procurement route |
Common evidence you can require |
| API manufacturers (commercial) |
Pyrazinamide API in bulk (25 kg, 50 kg, often with DMF/CEP where applicable) |
Direct purchase or distributor |
COA, GMP certificate, traceability, stability protocol, spec sheet |
| Specialty chemical producers |
Pyrazinamide for research and industrial use; some can qualify for pharma |
Purchase through chemical trading arms |
Purity/HPLC spec, heavy metals, residual solvents, polymorph control (if relevant) |
| Contract manufacturers / tollers |
Pyrazinamide made to a customer spec using internal chemistry |
Supplier qualification program |
Batch records, validation package, change-control process |
| Distributors / wholesalers |
Inventory sourced from API manufacturers |
Blanket PO with framework contracts |
Manufacturer of record on COA, GDP documentation, lot-level documentation |
| Local repackagers (where allowed) |
Repackaged API for lab or regional formulators |
Regional procurement |
Repackaging GMP statement and full COA transfer |
Which regions dominate pyrazinamide supply?
Pyrazinamide supply is concentrated in industrial chemical clusters where commodity fermentation-free small molecules are produced at scale.
| Region |
Why it matters for procurement |
Typical supply pattern |
| China |
Large base of small-molecule chemical synthesis and API capacity |
High volume, broad price range |
| India |
Multiple API producers and toll manufacturing |
Dossier-capable supply in pharma specs |
| Europe |
Lower-cost commodity capacity is smaller; emphasis on compliance for EU workflows |
Premium documentation, smaller volumes |
| MENA and LATAM |
Procurement often routed through distributors or importers |
Higher lead times for qualification lots |
What specs and documentation usually govern qualified pyrazinamide API supply?
Pyrazinamide is typically purchased against pharmacopoeial quality and internal QA specs. Buyers commonly request the following items in RFQs.
| Requirement |
What you should request |
| Pharmacopoeia compliance |
USP, BP, or EP compliance statement for each lot (as applicable) |
| Identity and assay |
HPLC/GC method reference, acceptance criteria for assay and identity |
| Impurities |
Spec for total impurities, individual impurity limits, and class of impurities |
| Residual solvents |
ICH Q3C-aligned residual solvent targets if synthesis/solvent system warrants |
| Heavy metals |
ICP or equivalent heavy metals limits |
| Water and other solids specs |
Loss on drying (LOD) or moisture content specs |
| Particle/powder properties (if used in solid dosage forms) |
Bulk density, tap density, particle size distribution if relevant to downstream processing |
| Microbial quality |
Usually limited for API unless a non-sterile formulation step or special route requires it |
| GMP and batch traceability |
Manufacturer GMP certificate and lot traceability from manufacturer of record |
| Stability |
At least initial stability data (e.g., 25C/60% RH, 30C/65% RH) and ongoing stability commitment |
How do buyers typically shortlist pyrazinamide suppliers?
Shortlists in pyrazinamide procurement usually hinge on two axes: (1) ability to supply consistent quality against a target pharmacopoeia and (2) documentation readiness for regulatory submission or inspection readiness.
| Shortlisting criterion |
Procurement impact |
| GMP footprint and audit history |
Speeds qualification and reduces re-sampling risk |
| Pharmacopoeial alignment |
Reduces formulation and release cycle friction |
| Impurity profile consistency |
Reduces batch rejection risk in downstream compression/coating |
| Lead time and batch availability |
Determines ability to support TB program demand cycles |
| Tech transfer support |
Enables change-control robustness when formulation sites need updates |
| Dossier assets |
Supports submissions when DMF/CEP-style filings exist |
What do “pharma-grade” pyrazinamide supplier setups look like?
For pyrazinamide, “pharma-grade” usually means the API supplier operates under GMP and sells material with lot-specific COA and stability/impurity characterization aligned to the buyer’s target pharmacopoeia.
A typical pharma supply package includes:
- COA with identity, assay, impurities, LOD/moisture, residual solvents (if applicable), heavy metals, and physical tests.
- GMP certificate covering API manufacturing.
- DMF/CEP and/or audit-ready quality package depending on market.
- Method appendices or at least method references to the pharmacopoeial/general approach used for testing.
- Stability evidence and declared retest period based on ongoing stability.
What supplier channels are commonly used to obtain pyrazinamide in practice?
| Channel |
Best fit |
Procurement downside |
| Direct from API manufacturer |
Long-term supply, stronger lot traceability |
Qualification workload and sometimes less responsive inventory visibility |
| Through a pharma distributor |
Faster ordering, easier replenishment |
You rely on distributor quality controls and manufacturer-of-record clarity |
| Toll manufacturing |
Custom spec and impurity tailoring |
Requires heavier validation and change-control governance |
| Multi-sourcing from commodity producers |
Cost control and volume security |
Higher QA burden for impurity profile and documentation consistency |
Key procurement reality for pyrazinamide
Pyrazinamide behaves like a commodity small molecule in many markets: buyers often manage risk by multi-sourcing, locking to firm specs, and insisting on lot-level documentation (COA plus GMP/traceability). Supplier qualification is less about synthetic novelty and more about quality system consistency and impurity and stability control.
Key Takeaways
- Pyrazinamide supply is dominated by commercial API manufacturers in China and India, plus distributors and toll manufacturers for qualification-driven sourcing.
- Qualified supply is governed by pharmacopoeial alignment, impurity profile consistency, and GMP/lot traceability rather than by proprietary technology.
- Procurement should prioritize supplier packages that include COA, GMP certificate, stability evidence, and impurity/residual solvent/heavy metal specs.
- Risk control for this commodity-style API comes from multi-sourcing plus lot-level documentation requirements.
FAQs
1) Is pyrazinamide treated like a specialty API or a commodity API for sourcing?
It is commonly sourced like a commodity small-molecule API, where price and documentation consistency drive supplier selection.
2) What documents matter most when qualifying a pyrazinamide API supplier?
A lot-level COA, the GMP certificate for the manufacturer of record, impurity/residual solvent/heavy metals specs, and stability evidence are the core qualification items.
3) Do distributors usually sell the same pyrazinamide API as the manufacturer?
Distributors typically source from an upstream manufacturer. The critical procurement control is ensuring the manufacturer of record is clearly identified on the COA and documentation packet.
4) What pharmacopoeia alignment is typically requested for pyrazinamide?
Buyers often request USP, BP, or EP alignment depending on market and regulatory pathway.
5) How do buyers reduce batch-to-batch variability risk with pyrazinamide?
They use tight specifications, request impurity profile and stability data, and apply a multi-source strategy with qualification cycles tied to lot release history.
References
[1] United States Pharmacopeia (USP). USP–National Formulary. General information and standards for pharmaceutical substances. (Accessed via USP resources).
[2] European Pharmacopoeia (Ph. Eur.). General information and standards for pharmaceutical substances. (Accessed via European Pharmacopoeia resources).
[3] British Pharmacopoeia (BP). General information and standards for pharmaceutical substances. (Accessed via BP resources).
